Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 350

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 350
---
784 |     |        | 292 |     | $      | - |     | $          | 1,036,557 |     | $           | (43,662,032 | ) |     | $             | (42,625,475 | ) |

See accompanying notes to the consolidated financial statements Reflects a 1-for-100 reverse stock split effective January 8, 2025 and a 1-for-20 reverse stock split effective June 13, 2025 F-34 CERO THERAPEUTICS HOLDINGS, INC. CONSOLIDATED STATEMENTS OF CASH FLOW

|                                                                                              |     | For the      
 period from  
 February 14, 
 2024 through 
 December 31, 
 2024         |             |   |     | For the      
 period from  
 January 1,   
 2024 through 
 February 13, 
 2024         |           |   |     | For the      
 year ended   
 December 31, 
 2023         |            |   |
|:---------------------------------------------------------------------------------------------|:----|:-------------|------------:|:--|:----|:-------------|----------:|:--|:----|:-------------|-----------:|:--|
|                                                                                              |     | -Successor   |             |   |     | -Predecessor |           |   |     | -Predecessor |            |   |
| Cash flows from operating activities:                                                        |     |              |             |   |     |              |           |   |     |              |            |   |
| Net loss                                                                                     |     | $            |  (7,732,212 | ) |     | $            |  (572,211 | ) |     | $            | (7,289,577 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities:                  |     |              |             |   |     |              |           |   |     |              |            |   |
| Gain from settlement of liabilities with vendors                                             |     |              |  (3,339,223 | ) |     |              |         - |   |     |              |          - |   |
| Depreciation expense                                                                         |     |              |     400,825 |   |     |              |    37,356 |   |     |              |    460,722 |   |
| Stock-based compensation                                                                     |     |              |